Jamjoom Pharmaceuticalsجمجوم فارما
- Price
- 160.40 SAR
- Fair value
- 57.12 SAR
- Discount to fair value
- −181%
- Mkt cap
- 11.23B
- P/E
- 24.2×
- P/B
- 6.54×
- EV
- 10.89B
- Div yield
- 2.16%
- ROE
- 27.0%
- Net margin
- 30.9%
Current price160.4SAR
Fair value (est., median)57.12SAR
UndervaluedFair valueOvervalued
+180.8% above fair valueWould need to fall ~64.4% to reach fair value.
Median ofDCF 111.34DDM 47.57Graham 57.12Residual Income 69.01Earnings Power 56.3
Health Check
64.9
Overall / 100
Good (66+)Caution (40–65)Risk (<40)
Rewards
- Strong return on equity (27%).
- Healthy balance sheet.
- Above-average growth expected.
Risks
- Trades 180.8% above estimated fair value.
- Low fair-value confidence — methods disagree or data is thin.
- Expensive on book (P/B 6.5×).
Scores are computed automatically from the real financial statements (Value from fair value; the rest from growth, profitability, balance sheet and dividends). A decision aid, not investment advice.
Price, corporate actions & news
Demo series
D — DividendS — Split▲ good · ▼ bad newstap a marker for detailsDemo series
Growth & profitability
Revenue, net income and margin.
RevenueNet incomeNet margin %tap a bar for figures
Key figures
Covers 4 years · FY2022–FY2025
| Metric | FY'22 | FY'23 | FY'24 | FY'25 | TTM'26 |
|---|---|---|---|---|---|
| Revenue | 916.67M | 1.10B | 1.32B | 1.50B | — |
| Net Income | 171.31M | 292.40M | 356.52M | 463.80M | 474.97M |
| Net Margin | 18.7% | 26.6% | 27.0% | 30.9% | — |
| Operating Cash Flow | 229.33M | 295.92M | 263.30M | 406.29M | — |
| OCF Margin | 25.0% | 26.9% | 20.0% | 27.1% | — |
| Capital Expenditure | 87.65M | 45.77M | 57.00M | 74.31M | — |
| Free Cash Flow | 141.67M | 250.14M | 206.31M | 331.97M | — |
| FCF Margin | 15.5% | 22.7% | 15.6% | 22.1% | — |
| FCF Conversion | 82.7% | 85.5% | 57.9% | 71.6% | — |
| EPS (Diluted) | 2.45/sh | 4.18/sh | 5.09/sh | 6.63/sh | 6.79/sh |
| Dividend / Share | 2.13/sh | 1.00/sh | 3.10/sh | 3.46/sh | — |
Dividend return (if you buy today)if you buy today
Dividend yield2.16%
Dividend / share3.46
If you invest
Shares (≈)62
Est. annual income214.52
At this rate, dividends alone return your capital in ~46.4 years.
Dividend history
Dividend / share & historical yield (SAR).
Dividend / share yield %tap a bar for figures
Quarterly dividends & yield
Per-share dividends by quarter, full-year total, and yield on the year's average price · SAR
| Year | Q1 | Q2 | Q3 | Q4 | Full year | Yield (avg) |
|---|---|---|---|---|---|---|
| 2026 | — | — | — | — | — | — |
| 2025 | — | — | — | — | 3.46 | — |
| 2024 | — | — | — | — | 3.10 | — |
| 2023 | — | — | — | — | 1.00 | — |
| 2022 | — | — | — | — | 2.13 | — |
Valuation breakdown
Fair value = median of the applicable methods (DCF، DDM، Graham، Residual Income، Earnings Power).
Each method below is a different lens on the same company — no single method dominates the result.
Discounted Cash Flow
Values the company from the future cash it's expected to generate. · Tap to adjust assumptions
111.34
Dividend Discount Model
Values the share from the dividends it's expected to keep paying. · Tap to adjust assumptions
47.57
Graham Number
A conservative benchmark built from earnings and book value. · Tap to adjust assumptions
57.12
Residual Income (justified P/B)
Values the profit the company earns above the cost of its equity. · Tap to adjust assumptions
69.01
Earnings Power Value
Values today's earning power as-is, assuming no growth. · Tap to adjust assumptions
56.30
DCF only is anchored on FY2025 — the latest year with positive cash flow that supports a value. The other methods (DDM, Graham, RIM, EPV) use current / normalized figures.
Fair Value (median)57.12
▸ Show assumptions▾ Assumptions
- Effective discount rate
- 10.49%
- CAPM cost of equity
- 10.50%
- Risk-free rate
- 4.50%
- Equity risk premium
- 6.00%
- DCF growth (stage 1)
- 8.00%
- DCF terminal growth
- 3.00%
- DCF forecast years
- 5
- DDM dividend growth
- 3.00%
Tune these per company in the Hajras Odoo backend; values recompute automatically.
Wealth simulator
What if you'd invested in Jamjoom Pharmaceuticals regularly?
Starting year
- Invested
- 1K/yr · 1K total(2026 → today · 1 yrs)
- your value today is
- 1K SAR
- Total return
- +2.2%(+2.2% Dividends · -0.0% Capital gain)
- Annualised (IRR)
- +4.9%
Invested1KSAR
Dividends22SAR
Capital gain-0SAR
InvestedCapital gainDividendstap a bar for figures
Community Notes0
No notes yet. Be the first to share a thesis.